Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants ≥ 40 years of age at baseline visit~* Patients with confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD)~* Patients who have been on Spiriva® HandiHaler® for ≥ 6 weeks at baseline visit~* Patients for whom a switch from Spiriva® HandiHaler® to Spiriva® Respimat® was planned prior to study inclusion. If additional inhalative COPD drugs (AICDs) are used: AICD treatment must have been stable for at least 6 weeks before study inclusion~* Signed written informed consent form to participation~Exclusion Criteria:~* Patients who have contraindications to Spiriva® Respimat® according to the current prescribing information label/ summary of product characteristics (SmPC)~* Patients who have signs of a current, acute respiratory tract infection 2 weeks prior visit 1~* Patients for whom further follow-up will not be possible at the enrolling site during the planned observational period (of approximately 8 weeks)~* Patients with confirmed diagnosis of only asthma~* Patients who had \> 1 moderate to severe exacerbation(s) within the last 6 weeks prior to study inclusion~* Patients who are pregnant or breastfeeding~* Patients participating in an ongoing interventional study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients switching from Spiriva® HandiHaler® to Spiriva® Respimat® (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).